Changes in Beneficial Ownership · 4
Cellectar Biosciences, Inc.
CLRBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2620095-8_4seq1.xml
Filing details
- Report period
- 2026-07-07
- Issuer
- Cellectar Biosciences, Inc.
- Issuer CIK
- 0001279704
- Trading symbol
- CLRB
Reporting owner 1
- Name
- DRISCOLL FREDERICK W
- Reporting owner CIK
- 0001129890
- Relationship
- Director
- Address
- C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy) | 2.70 | 2026-07-07 | A · Form 4 | 25,000 | A | 0 | [F1] | 2036-07-07 | Common stock | 25,000 | 25,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.↩ 1
Signature 1
- Signed
- /s/ Chad Kolean, attorney-in-fact for Frederick Driscoll
- Date
- 2026-07-08
Company context
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.
Current securities
Recent company filings
- SCHEDULE 13G - filed by Caligan Partners LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by STEMPOINT CAPITAL LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by Bleichroeder LP regarding Cellectar Biosciences, Inc.Aug 13, 2026
- Results of Operations and Financial ConditionAug 13, 2026